Corcept Therapeutics stock plunges after loss in patent battle with with Teva

Corcept Therapeutics (NASDAQ:CORT) plummeted 38% in after-hours buying and selling on Friday after a loss in a patent trial with Teva Prescribed drugs (NYSE:TEVA) over a patent for Cushing’s syndrome drug Korlym.

The courtroom discovered that Corcept (CORT) hadn’t met its burden of proving induced infringement, in line with a courtroom ruling late Friday by Choose Renée Marie Bumb of the US District Court docket for the District of New Jersey.

“ORDERED that Teva has not infringed, and that Teva’s making, utilizing, providing to promote, promoting, or importing Teva’s generic mifepristone product won’t infringe, claims 10–13 of the ʼ214 Patent or claims 1, 6, 7, and 9 of the ’800 Patent,” the choose wrote within the opinion on Friday.

The courtroom ruling comes after a trial in late September, which despatched Corcept (CORT) shares plunging 17% on Sept. 17.

Corcept (CORT) has been in a patent battle with Teva (TEVA) over a patent for Cushing’s syndrome drug Korlym, marketed by Corcept. In December 2021 Teva misplaced an try and invalidate a mother or father for Korlym.

Corcept (CORT) initially sued Teva (TEVA) in federal courtroom in March 2018 to forestall it from advertising a generic model of Korlym.

Corcept’s (CORT) brief curiosity is eighteen%.

Extra on Corcept Therapeutics